Confirmatory Phase 3 Clarity Ad Data To Be Evaluated By Fda In Determining Whether To Convert Accelerated Approval Of Leqembi To A Traditional ApprovalPriority Review Accelerates Fda Review Time With A Prescription Drug User Fee Act (Pdufa) Target Action On July 6, 2023 Eisai Co., Ltd. And Biogen Inc. Announced Today That The U.S. Food And Drug Administration (Fda) Has Accepted Eisai
